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The development of a complementary pathway
for the synthesis of aliskiren†
Le-Le Li,a,b Jin-Ying Ding,a Lian-Xun Gaoa and Fu-She Han*a,c
The synthesis of aliskiren (1), a recently marketed drug for the treatment of hypertension, is presented.
The focus of our synthetic eﬀort is to develop an eﬃcient pathway for the synthesis of (2S,7R,E)-2-iso-
propyl-7-(4-methoxy-3-(3-methoxypropoxy) benzyl)-N,N,8-trimethylnon-4-enamide (2a), which has been
used as the advanced intermediate toward aliskiren. After an extensive investigation of three diﬀerent
strategies designed to construct the E-oleﬁn functionality in 2a by employing the oleﬁn cross-metathesis,
Horner–Wadsworth–Emmons (HWE), and Julia-type oleﬁnations, we have established a new protocol for
the synthesis of 2a with a substantially improved overall eﬃciency in terms of the yield (ca. 33%), and dia-
stereo- and E/Z-selectivity. The key transformations were the Evans chiral auxiliary-aided asymmetric allyl-
ation for the synthesis of the appropriate chiral intermediates in excellent enantiomeric purity of higher
than 97% ee and a modiﬁed Julia–Kocienski oleﬁnation for the highly selective construction of E-2a with
up to 13.6 : 1 E/Z ratio from the chiral intermediates. Consequently, the results provide an appealing
option for the synthesis of aliskiren.
Introduction
Aliskiren 1 (Scheme 1) is a novel non-peptidic renin inhibitor1
and has been marketed as an orally active drug for the treat-
ment of hypertension.2 This molecule features the presence of
four chiral centers in an aliphatic carbon chain, which renders
the synthesis of this molecule extremely challenging. Neverthe-
less, the structural complexity as well as the fascinating bio-
logical activity of aliskiren has stimulated tremendous interest
of the community of synthetic and medicinal chemistry since
its discovery.3 Among a number of synthetic methods being
reported,3 the development of an eﬀective approach for the
construction of the advanced intermediate 2a or 2b
(Scheme 1), whose structure contains two chiral centers and
an E-olefin, has been the focus of many investigations because
these intermediates can be flexibly converted into aliskiren
with high regio- and stereoinduction.3h
So far, three typical strategies have been developed for
accessing 2. These include the coupling of vinyl halide 3 with
a Grignard reagent generated from alkyl halide 43r–t (Path A),
the base-promoted substitution reaction of aryl ketone 5 and
allylic bromide 63p,q (Path B), or the cross-metathesis of olefins
7 and 83d (Path C). Notably, the third protocol (Path C)
Scheme 1 Structures of aliskiren 1, the key intermediate 2 and the
general synthetic strategies.
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established by Hanessian3d could allow for a rapid synthesis of
2b in five linear steps and in 38% overall yield from a known
intermediate. Despite these important advances, the develop-
ment of a more eﬃcient synthesis remains highly desired
resulting from at least one of the following concerns of the
extant protocols such as the eﬀective construction of C2 and
C7 chiral centers, or the E olefin.
After a careful analysis of the advantages and disadvantages
of the reported approaches, we thought that the key for an
eﬃcient synthesis of 2 should rely on the establishment of
such a pathway that is capable of not only installing the chiral
centers with highly enantiomeric purity, but also constructing
the olefin moiety in high E-selectivity. Thus, three possible
routes were designed which we anticipated to construct the
E-2a at the late stage through the olefin cross-metathesis,
Horner–Wadsworth–Emmons (HWE), or Julia-type olefination
by employing the appropriately synthesized chiral precursors.
An extensive and detailed investigation into these synthetic
routes led eventually to the discovery that a pathway involving
the Evans asymmetric allylation and Julia–Kocienski olefina-
tion as the key transformations could be a highly appealing
option for the eﬃcient synthesis of 2a. The notable advantages
oﬀered by this new approach are that 2a could be furnished in
excellent E/Z selectivity of up to 13.6 : 1 from the appropriately
synthesized chiral precursors with excellent enantiomeric
purity of higher than 97% ee. In addition, high overall yield of
ca. 33% could be obtained for 2a in ten linear steps from the
commercially available materials. These advantages make the
current approach one of the appealing options for the eﬃcient
synthesis of aliskiren. Finally, the synthesis of aliskiren from
the advanced intermediate 2a has also been successfully
demonstrated according to the known methods.3p,s Herein, we
present the detailed results of our investigation.
Results and discussion
Synthesis of 2a via the olefin cross-metathesis strategy
At the outset of our investigation, we planned to synthesize 2a
via the olefin cross-metathesis strategy. Although a general
rule for accurately predicting the selectivity of olefin cross-
metathesis such as homo- and heterogeneous selectivity, and
cis/trans stereoselectivity remains unavailable,4 intensive
studies have demonstrated that the outcome of the cross-meta-
thesis is markedly influenced by altering the steric and elec-
tronic properties of either reaction partners, or by choosing an
appropriate catalyst.5 Thus, a series of chiral olefin precursors
with diﬀerent steric bulkiness were synthesized by utilizing
the Evans asymmetric allylation as the key transformation.6 As
outlined in Scheme 2, the reaction of commercially available 9
with allyl bromide (condition a) or 3,3-dimethylallyl bromide
(condition b) proceeded smoothly to give 10a and 10c, respect-
ively, in excellent yields. 10b was readily prepared via a two-
step procedure involving the allylation of 9 with trans-1,4-
dibromo-2-butene, aﬀording 10b′, followed by reductive
removal of the bromo group with NaBH3CN.
7 Hydrolytic
cleavage of Evans’ chiral auxiliary in 10a–c aﬀorded the corres-
ponding carboxylic acids 11a–c, which could be synthesized on
a scale of dozens of grams with constant eﬃciency and serve
as the versatile intermediates for the preparation of various
chiral precursors in our following studies. Accordingly, 11a–11c
were converted into the amides 12a–c and Weinreb amides
13a–c, respectively, through their acyl chlorides.8 The Weinreb
amides 13a–c were further reacted with the aryl lithium, gener-
ated in situ from aryl bromide 143d and n-BuLi, to give the aryl
ketones 15a–c. The enantiomeric purity of compound 15a was
higher than 97% ee as determined by chiral HPLC analysis
(see ESI†), reflecting that the Evans asymmetric allylation was
a powerful option for the synthesis of chiral precursors.
Finally, reduction of 15a–c by a combined use of LiAlH4 and
AlCl3 aﬀorded the olefin 16a–c.
3d,9
With the two types of olefins 12 and 16 in hand, we investi-
gated the cross-metathesis reaction. Screening of the catalysts
and solvents were carried out using 12a and 16a as the model
substrates. Some representative results are summarized in
Table 1. The Grubbs 1st generation catalyst (1st G) was less
eﬀective with the best result obtained in 18% yield in CH2Cl2
Scheme 2 Synthesis of oleﬁns 12a–c and 16a–c. Reagents and con-
ditions: (a) LiHMDS (1.2 equiv.), allyl bromide (1.5 equiv.), THF, −78 °C to
rt, 96%; (b) LiHMDS (1.5 equiv.), 3,3-dimethylallyl bromide (1.5 equiv.),
THF, −78 °C to rt, 96%; (c) LiHMDS (1.2 equiv.), trans-1,4-dibromo-2-
butene (3.0 equiv.), THF, −78 °C to rt, 90%; (d) NaBH3CN (3.0 equiv.),
THF, 60 °C, 94%; (e) LiOH (2.0 equiv.), H2O2 (4.0 equiv.), THF–H2O, rt,
91% for 11a; 88% for 11b; 88% for 11c; (f ) (COCl)2 (3.0 equiv.), DMF
(cat.), CH2Cl2, then Me2NH·HCl (2.0 equiv.), DMAP (5 mol%), Et3N
(4.0 equiv.), rt, 86% for 12a; 69% for 12b; 72% for 12c; (g) (COCl)2
(3.0 equiv.), DMF (cat.), CH2Cl2, then MeONH(Me)·HCl (2.0 equiv.), DMAP
(2 mol%), Et3N (4.0 equiv.), rt; (h) 14 (2.0 equiv.), n-BuLi (2.0 equiv.), THF,
−78 °C; (i) AlCl3 (2.0 equiv.), LiAlH4 (1.0 equiv.), Et2O, rt; three-step yield
for 16a: 70%; for 16b: 38%; for 16c: 26%.
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(entry 1). In contrast, the Grubbs 2nd generation catalyst
(2nd G) exhibited a much higher activity, giving the cross-meta-
thesis product 2a in high yield and moderate to moderately
high E/Z selectivity in CH2Cl2 and n-hexane solvents (entries 2
and 3). In addition, the Hoveyda–Grubbs 2nd generation cata-
lyst (2nd H–G) could also aﬀect the reaction although the
overall eﬃciency was somewhat lower than the Grubbs 2nd
generation catalyst (entries 4 and 5). Further examination of
various solvents (entries 6–9) in the presence of the Grubbs
2nd generation catalyst revealed that petroleum ether (PE) was
also a promising solvent (entry 6). Thus, through these pre-
liminary studies, we found that CH2Cl2 or PE solvents coupled
with the use of Grubbs 2nd or Hoveyda–Grubbs 2nd gene-
ration catalysts were a promising combination for the cross-
metathesis reaction. Here, it should be mentioned that the
structure of the major E-2a was determined by NMR and
HRMS analyses using a suﬃciently pure sample isolated care-
fully from the mixture of E and Z-2a by column chromato-
graphy on 200–300 mesh silica gel (E/Z >200 : 1 as determined
by HPLC). The corresponding Z-2a was identified by the
1H-NMR combined with HPLC-MS analyses of a mixture of
E- and Z-2a. The data were identical to the reported literature.3s
Having discovered the suitable solvents and catalysts, we
examined the eﬀect of additives on the reaction since it has
been observed that, in many cases, the eﬃciency of olefin
cross-metathesis was dramatically influenced by varying the
additives.10 Accordingly, an array of Lewis and Brønsted acids,
bases, and oxidants were extensively examined. Unfortunately,
most of the acidic and basic additives exhibited a detrimental
eﬀect both to the yield and selectivity (data not shown).
However, the addition of 1,4-benzoquinone (BQ) aﬀorded an
improved yield in PE although the E/Z selectivity was some-
what diminished (Table 2, entries 1 and 2). To improve the
stereoselectivity, we inspected the cross-metathesis of the steri-
cally more hindered olefins. However, the results showed that
the reaction was less sensitive to the steric nature of the sub-
strates in the PE solvent. Both the yield and E/Z selectivity
under various combinations of olefins such as 12a with
1-methyl olefin 16b (entries 3 and 4), 1-methyl olefin 12b with
16a (entries 5 and 6), and 1-methyl olefin 12b with 1-methyl
olefin 16b (entries 7 and 8) were almost identical to those
aﬀorded by the combination of 1-unsubstituted olefin 12a and
16a. Interestingly, an increased E/Z ratio was observed when
the PE solvent was replaced by CH2Cl2 (entries 9 and 10),
although the yield was somewhat diminished. At this conjunc-
ture, the eﬀect of the molar equivalents of BQ on the reaction
was re-optimized in order to improve the overall eﬃciency
(entries 10–13). We found that the use of 60 mol% of BQ could
aﬀord the best E/Z ratio of up to 7.0 : 1 without decrease in the
yield (entry 11). Finally, it should be mentioned that ineﬀective
cross-metathesis was observed when either of the 1,1-dimethyl
olefins 12c or 16c was used as the cross-metathesis partner.
During the course of our investigation, we noted that
Hanessian and co-workers employed a very similar cross-meta-
thesis reaction as one of the key transformations in their syn-
thesis of aliskiren.3d Namely, in the presence of 20 mol% of
the Hoveyda–Grubbs 2nd generation catalyst, the cross-meta-
thesis of 16a and the olefin 17 bearing an ester functionality
delivered the cross product 2b in 60% yield and ca. 6.1 : 1 E/Z
ratio under reflux for 3 days (Scheme 3). To compare with
Table 1 Screening of catalysts and solventsa
Entry Catalyst Solvent
Yieldb
(%) E/Zc
1 1st G CH2Cl2 18 —
d
2 2nd G CH2Cl2 76 3.1
3 2nd G n-Hexane 66 5.2
4 2nd H–G CH2Cl2 65 3.3
5 2nd H–G n-Hexane 56 3.3
6 2nd G PE 66 5.5
7 2nd G PhMe 53 4.2
8 2nd G (CH2)2Cl2 30 —
d
9 2nd G Cyclohexane 28 —d
a Reaction conditions: 16a (0.5 mmol, 1.0 equiv.), 12a (1.5 mmol,
3.0 equiv.) and the catalyst (5 mol %) under reflux. b Isolated yield.
c E/Z ratio was determined by HPLC on a Hypersil ODS C18 column.
dNot determined.
Table 2 Cross-metathesis of various combinations of 12 and 16 in the
presence of a BQ additivea
Entry Substrate Catalyst Solvent
Yieldb
(%) E/Zc
1 12a/16a 2nd H–G PE 88 3.9
2 12a/16a 2nd G PE 72 4.2
3 12a/16b 2nd H–G PE 72 4.6
4 12a/16b 2nd G PE 78 4.2
5 12b/16a 2nd H–G PE 82 3.0
6 12b/16a 2nd G PE 80 4.2
7 12b/16b 2nd H–G PE 72 4.1
8 12b/16b 2nd G PE 80 4.3
9 12b/16b 2nd H–G CH2Cl2 68 5.7
10 12b/16b 2nd G CH2Cl2 62 6.6
11 12b/16b 2nd G CH2Cl2 62 7.0
d
12 12b/16b 2nd G CH2Cl2 67 6.8
e
13 12b/16b 2nd G CH2Cl2 66 6.7
f
aUnless otherwise noted, the reaction conditions were: 16 (0.2 mmol,
1.0 equiv.), 12 (0.8 mmol, 4.0 equiv.), catalyst (5 mol%), BQ (50 mol%)
in a solvent under reflux for 24 h. b Isolated yield. c The ratio of E/Z was
determined by HPLC on a Hypersil ODS C18 column. d 60 mol% of BQ
was used. e 70 mol% of BQ was used. f 80 mol% of BQ was used.
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Hanessian’s protocol, our cross-metathesis is somewhat more
eﬀective for the construction of analogue 2a in terms of yield,
E/Z selectivity, the catalyst loading (5 mol%) and the reaction
time, presumably resulting from the diﬀerent properties of
amide olefin 12a vs. the ester olefin 17 and the presence of a
BQ additive in the reaction system. However, both the yield
and E/Z selectivity of our procedure remained not suﬃciently
high. In addition, the need of 5 mol% of the Grubbs 2nd gene-
ration catalyst is still a high loading. These drawbacks are
apparent obstacles when practical application for the synthesis
of aliskiren is under consideration. As such, we decided to
search an alternative pathway toward synthesizing 2a more
eﬃciently.
Synthesis of 2a via the HWE olefination strategy
Considering that Horner–Wadsworth–Emmons (HWE) olefina-
tion has various advantages such as high E-selectivity and the
ease of separation of the dialkyl phosphate by-product for the
preparation of alkenes,11 we investigated its application for the
synthesis of 2a. Accordingly, oxidation of the olefins 12a and
16a gave the aldehydes 18 (97% ee, see ESI†) and 19, respect-
ively, in high yield (Scheme 4). Here, it should be mentioned
that for the oxidation of 16a, the addition of an organic base
such as 1,4-diazabicyclo[2,2,2]octane (DABCO) was crucial for
improving the yield of 19 by suppressing the formation of
various side products.12
For the transformation of 18 or 19 to the corresponding
phosphonate esters 20 or 22, we investigated the copper-cata-
lyzed reductive coupling of dialkyl phosphite with N-tosyl-
hydrazone generated in situ from aldehyde and N-tosylhydrazine
as disclosed independently by Tang and Liang’s groups.13 This
new protocol takes the advantage of furnishing the phosphon-
ate esters directly from the aldehydes via a two-step one-pot
operation without the isolation of N-tosylhydrazone intermedi-
ates. Therefore, if the protocol works well for our substrates,
it would provide a straightforward option for the synthesis
of the desired phosphonate esters 20 or 22 to compare with
the conventional procedures, which, in principle, required a
multi-step transformation involving the reduction of the alde-
hyde to alcohol, conversion of alcohol to halide followed by
the Arbuzov reaction14 or by the nucleophilic displacement
of phosphinic halide with an organometallic reagent such
as organolithium and Grignard reagent formed from the
halide.15 Initial trials showed that the copper-catalyzed coup-
ling of dialkyl phosphite with the N-tosylhydrazone formed
from the amide aldehyde 18 and N-tosylhydrazine for produ-
cing 20 was ineﬀective under the reported conditions presum-
ably due to the influence of the amide functionality in 18.
However, 19 could be converted into the desired phosphonate
ester 22 in moderate yield (40–55%) via a one-pot reaction
through the intermediate 21. After a further optimization of
the reported reaction conditions, we could obtain 22 in 80%
yield by replacing the K2CO3 or Cs2CO3 base with K3PO4 and
the dioxane solvent with toluene, respectively.
Next, the HWE olefination of 22 and 18 was examined
(Scheme 5). Disappointedly, extensive trials showed the reac-
tion did not proceed under an array of conditions – by varying
the bases, solvents, temperature and additives. 22 was recovered
completely in many cases. In stark contrast, control experi-
ments demonstrated that phosphonate 22 reacted uneventfully
with allyl bromide 23 to give the allylated phosphonate 24 in
Scheme 3 Cross-metathesis reaction reported by Hanessian et al.3d
Scheme 4 Synthesis of 20 and 22. Reagents and conditions: (a) OsO4
(1 mol%), NaIO4 (4 equiv.), THF–H2O (2 : 1), 0 °C, 69%; (b) OsO4 (1 mol%),
NaIO4 (4.0 equiv.), DABCO (4.0 equiv.), THF–H2O (2 : 1), 0 °C, 89%;
(c) TsNHNH2 (1.0 equiv.), toluene, rt, 45 min; then (EtO)2P(O)H
(5.0 equiv.), CuI (10 mol%), K3PO4 (6.0 equiv.), reﬂux, 80%.
Scheme 5 HWE reaction of 18 and 22, and control experiments.
Reagents and conditions: (a) allyl bromide (5.4 equiv.), n-BuLi
(1.5 equiv.), THF, −78 °C to rt, 69%; (b) 25 (1.5 equiv.), n-BuLi (1.5 equiv.),
THF, −78 °C to rt, 74%.
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69% yield. On the other hand, reaction of aldehyde 18 with
methyl 2-(diethoxyphosphoryl)acetate 25 could also proceed
eﬃciently to produce the α,β-unsaturated ester amide 26 in
74% yield. These results imply that the ineﬀective HWE reac-
tion between 18 and 22 may be resulted from the increased
steric bulkiness of both substrates. The detailed reasons
deserve a further clarification in our laboratory. Thus, we had
to give up this investigation and turn our attention to explore
other possible approaches.
Synthesis of 2a via the Julia–Kocienski olefination
The Julia-type olefination is also one of the most popularly
used protocols for accessing olefins.16 Typically, the Julia–
Kocienski olefination has been demonstrated to be a powerful
tool for the synthesis of E-form of nonconjugated 1,2-disubsti-
tuted alkenes.17 Owing to the exemplified advantages, we con-
ceived to synthesize 2a by employing the Julia–Kocienski
reaction. Accordingly, the aldehyde 19 was reduced to alcohol
27 with LiBH4 in quantitative yield (Scheme 6). Condensation
of 27 with 1-phenyl-1H-tetrazole-5-thiol 29a under Mitsunobu
conditions18 aﬀorded the sulfide 30a in high yield. Alterna-
tively, the conversion of alcohol 27 into the corresponding
tosylate 28 followed by the substitution reaction with 29a–c
was also an eﬃcient option for the synthesis of various sul-
fides 30a–c. Finally, oxidation of the sulfides19 proceeded
smoothly to give sulfones 31a–c.
Next, we examined the Julia–Kocienski olefination of sul-
fones 31 with aldehyde 18. The screening of the reaction con-
ditions was carried out using 31a and 18 as substrates. Some
representative data are shown in Table 3. A brief screening of
the solvents showed that THF was a better option in terms of
yield and E/Z selectivity (entries 1–3). In addition, among the
three bases being examined (entries 3–5), NaHMDS was the
optimal one which could aﬀord 2a in high yield and moderate
E/Z selectivity (entry 4). On the basis of these preliminary
results, the reaction parameters were re-examined using
NaHMDS as the base. Delightedly, we found that the E/Z
selectivity could be improved markedly from ca. 5.1 : 1 to 9.9 : 1
without aﬀecting the yield when DME instead of THF was used
as the solvent (entry 4 vs. 6). An investigation into the eﬀect of
diﬀerent sulfones decorated by various R groups in the tetra-
zole moiety revealed that 31a (R = Ph) and 31b (R = tBu) could
aﬀord the product in almost equally good eﬃciency as seen
from the yield and E/Z selectivity (entries 6 and 7). However,
31c (R = Me) gave a decreased E/Z ratio although the yield was
slightly increased (entry 8). Considering that 31a could be syn-
thesized more eﬃciently than 31b due to the higher yield for
the preparation of its precursor 30a (Scheme 6), sulfone 31a
was used as the substrate to screen the reaction conditions
toward further improving the reaction eﬃciency. At this con-
juncture, we inspected the eﬀect of phase transfer catalysts
such as crown ethers since a recent report20 has exemplified
that the presence of such additives could influence consider-
ably the outcome of the Julia olefination. Indeed, we observed
Scheme 6 Synthesis of sulfones 31. Reagents and conditions: (a) LiBH4
(1.2 equiv.), THF, rt, quant.; (b) 29a (2.0 equiv.), PPh3 (1.5 equiv.), DEAD
(2.0 equiv.), THF, −40 °C, 80%; (c) TsCl (1.1 equiv.), Et3N (3 equiv.), DMAP
(0.05 equiv.), rt, 96%; (d) K2CO3 (5 equiv.), 29 (2.0 equiv.), 50 °C, 95% for
30a, 60% for 30b and 85% for 30c; (e) (NH4)6Mo7O24·4H2O (20 mol%),
30% H2O2 (20 equiv.), EtOH, rt, 94% for 31a, for 90% 31b and 98%
for 31c.
Table 3 Optimization of the Julia–Kocienski oleﬁnation of sulfone 31
and aldehyde 18a
Entry 31 Base Solvent Add. (equiv.)
Yield
(%)b E/Zc
1 31a LiHMDS Toluene — 86 2.1
2 31a LiHMDS DMF — 57 2.4d
3 31a LiHMDS THF — 86 3.3e
4 31a NaHMDS THF — 82 5.1
5 31a KHMDS THF — 73 3.4
6 31a NaHMDS DME — 83 9.9 f
7 31b NaHMDS DME — 88 9.4
8 31c NaHMDS DME — 92 7.4
9 31a NaHMDS THF 18-C-6 (2.0) 54 7.4
10 31a NaHMDS DME 18-C-6 (2.0) 58 14.5
11 31a NaHMDS DME 15-C-5 (2.0) 49 8.5
12 31a NaHMDS DME 18-C-6 (1.0) 70 13.9
13 31a NaHMDS DME 18-C-6 (0.5) 70 13.6
14 31a NaHMDS DME 18-C-6 (0.25) 80 13.6
aUnless otherwise noted, the reaction conditions: 31 (0.2 mmol,
1.0 equiv.), 18 (0.8 mmol, 4.0 equiv.), base (0.4 mmol, 2.0 equiv.),
additive (x equiv.) in solvent from −78 °C (in THF) or −70 °C (in DME)
to r.t. b Isolated yield. c The ratio of E/Z was determined by HPLC on a
Hypersil ODS C18 column. d The reaction was performed from −40 °C
to r.t. since the reaction mixture was slightly frozen under lower
temperature. e Average value of two runs. f The reaction was performed
from −55 °C to r.t. since the reaction mixture was slightly frozen under
lower temperature. Abbr.: LiHMDS = lithium hexamethyldisilazide;
NaHMDS = sodium hexamethyldisilazide; KHMDS = potassium
hexamethyldisilazide; DMF = N,N-dimethylformamide; THF =
tetrahydrofuran; DME = 1,2-dimethoxyethane; 18-C-6 = 18-crown-6;
15-C-5 = 15-crown-5.
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that the addition of 2.0 equiv. of 18-crown-6 could lead to a
substantial increase in E/Z selectivity either in THF or in DME
(entries 4 vs. 9, and 6 vs. 10). Notably, the E/Z ratio was
improved to 14.5 : 1 in DME, although the yield of 2a signifi-
cantly diminished in this solvent (entry 10). As a comparison,
the addition of 15-crown-5 exhibited a detrimental eﬀect both
to the yield and stereoselectivity (entry 11). Finally, a brief
optimization of the molar equivalents of 18-crown-6 (entries
12–14) revealed that the presence of 0.25 equiv. of 18-crown-6
could deliver 2a not only in high yield (80%) but also in excel-
lent E/Z selectivity (13.6 : 1) (entry 14).
Having established an eﬃcient route for the synthesis of
the advanced intermediate 2a, we implemented the final syn-
thesis of aliskiren (1) by referring to the reported procedur-
es.3p,s Namely, bromolactonization of 2a with NBS followed
by a simple recrystallization of the crude product aﬀorded
pure lactone 32 (Scheme 7). The NMR spectroscopic and the
specific rotation value of the intermediate 32 were consistent
with the reported data {synth., [α]20D +39.2 (c 1.0, CHCl3);
Lit.,3s [α]25D +44.2 (c 1.0, CHCl3)}. The data further confirmed
that E-2a is obtained as the major product from the Julia–
Kocienski olefination. Substitution of Br with NaN3 and amid-
ation of the lactone moiety in 32 proceeded uneventfully to
give the azide 33. Finally, hydrogenolysis of the N3 group in
33 gave aliskiren 1. Here, we should mention that, although
not investigated carefully, it seems that the free aliskiren
is not suﬃciently stable during hydrogenolysis and the
subsequent handling. A small amount of the less polar by-
product was often formed as indicated by the TLC monitor-
ing. This may result from the partial oxidation of the product
under ambient conditions. After some trials, it was found
that the addition of ethanolamine in the reaction system and
trapping the product with HCl solution in MeOH could aﬀord
pure aliskiren as its HCl salt. The NMR data of both the HCl
and hemifumarate salt of aliskiren is identical to the reported
data.3j,u
Conclusions
In conclusion, we have developed an alternative route for the
synthesis of the advanced intermediate 2a toward aliskiren.
From the commercially readily available 9, 2a could be syn-
thesized in 33% overall yield via a ten-step procedure.
Although the steps of our synthesis are relatively longer and
the overall yield is slightly lower than the protocol developed
by Hanessian for the synthesis of analogue 2b (5 linear steps
from a known intermediate in 38% overall yield),3d the
pathway developed herein could aﬀord the product with a
remarkably improved E/Z selectivity (E/Z = 13.6 : 1). Moreover,
the enantiomeric purity of the key chiral precursors 16a syn-
thesized through the Evans chiral auxiliary-aided asymmetric
allylation in this work is higher than that synthesized through
the Stoltz Pd-catalyzed asymmetric protocol3d,21 (97% vs. 90%
ee). Owing to these advantages, we believe that the method
presented in this work should be a complementary route for
the synthesis of aliskiren. The synthesis of aliskiren from 2a
has also been demonstrated according to the known proce-
dures.3p,s Further optimization of the process toward large
scale synthesis is currently underway.
Experimental section
General methods
Unless otherwise noted, all solvents were purified according to
the standard procedures. Allyl bromide, (COCl)2, and (EtO)2POH
were distilled prior to use. Other reagents were of reagent grade
and used without purification. The 1H-NMR spectra were
recorded at 600, 400, or 300 MHz (Bruker AV) in CDCl3 or
DMSO-d6. The
13C-NMR spectra were recorded at 150 or
100 MHz in CDCl3 or DMSO-d6. The
31P-NMR spectra were
recorded at 162 MHz in CDCl3. Chemical shifts are given in
ppm relative to TMS or the appropriate solvent peak. Coupling
constants ( J values) are reported in hertz (Hz). High resolution
mass spectra (HRMS) are measured using an IonSpec Ultima 7.0
TFT-ICR-MS instrument (IonSpec, USA) with a Waters Z-spray
source. HPLC analysis was performed on Shimadzu (LC 20AD,
UV detection monitored at 254 nm) or Shimadzu (LC 6AD, UV
detection monitored at 254 nm). C18 column for E/Z selectivity
measurements (Hypersil ODS 5 μm, 4.6 mm × 250 mm) was pur-
chased from Dalian Elite Analytical Instruments Co., Ltd.
A Chiralpak AD-H column for enantiomeric excess measurements
was purchased from Daicel Chemical Industries, Ltd. The optical
rotation value was measured by a Perkin Elmer 341LC polari-
meter operating on the sodium D-line (589 nm), using a
100 mm path-length cell and are reported as: [α]TD (concen-
tration in g per 100 mL, solvent). Column chromatography was
performed on silica gel 100–200 mesh or 200–300 mesh.
General synthesis of 2a via the olefin cross-metathesis
A round-bottom flask equipped with a condenser and a mag-
netic stirrer bar was charged with 16 (1.0 equiv.), 12 (3.0 or
4.0 equiv.), additives (added or not) and 5 mol% of catalyst under
Scheme 7 Synthesis of aliskiren (1).
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a nitrogen atmosphere. The reaction vessel was flushed with
nitrogen. Then a solvent was added via a glass syringe. The
resulting reaction mixture was refluxed for 24 h under a nitro-
gen atmosphere. The solvent was then removed under reduced
pressure. The product was isolated by column chromatography
on silica gel with ethyl acetate and hexane (v/v = 1 : 5) as an
eluent to give 2a as a slightly yellow oil.
General synthesis of 2a via the Julia–Kocienski olefination
A dried tube equipped with a magnetic stirrer was charged
with 31 (0.2 mmol, 1.0 equiv.) and flushed with nitrogen. Then
a dried solvent (2.5 mL) was added via a glass syringe. Unless
otherwise noted, the solution was cooled to −70 °C and then a
solution of the MHMDS base (0.4 mmol in solvent (1 mL),
where M = Li, Na, or K) was added dropwise. After being
stirred at −70 °C for 1 h, aldehyde 18 (0.8 mmol in solvent
(1 mL)) was added dropwise. The resulting reaction mixture
was stirred at −70 °C for 1 h and then allowed to warm gradu-
ally to room temperature and stirred for a few hours until 31
had disappeared, as monitored by TLC. The reaction mixture
was quenched with brine and diluted with CH2Cl2. The
organic layer was separated, dried over Na2SO4, filtered, con-
centrated and purified by flash column chromatography on
silica gel with a mixed ethyl acetate and hexane (v/v = 1 : 2) as
an eluent to give 2a as a slightly yellow oil.
Acknowledgements
Financial support from the NSFC (21272225), and the Key Lab-
oratory of Synthetic Chemistry of Natural Substances, SIOC, is
acknowledged.
References
1 (a) R. Goeschke, V. Rasetti, N. C. Cohen, J. Rahuel,
M. Grütter, S. Stutz, W. Fuhrer, J. M. Wood and
J. Maibaum, 15th International Symposium on Medicinal
Chemistry, Edinburgh, 1998; (b) J. Rahuel, V. Rasetti,
J. Maibaum, H. Rüeger, R. Göschke, N. C. Cohen, S. Stutz,
F. Cumin, W. Fuhrer, J. M. Wood and M. G. Grütter, Chem.
Biol., 2000, 7, 493–504.
2 (a) J. Maibaum and D. L. Feldman, in Annual Reports in
Medicinal Chemistry, ed. E. M. John, Academic Press,
2009, vol. 44, pp. 105–127; (b) C. Jensen, P. Herold and
H. R. Brunner, Nat. Rev. Drug Discovery, 2008, 7, 399–410;
(c) H. M. Siragy, S. Kar and P. Kirkpatrick, Nat. Rev. Drug
Discovery, 2007, 6, 779–780.
3 For selected examples, see: (a) R. Lakerveld, B. Benyahia,
P. L. Heider, H. Zhang, A. Wolfe, C. J. Testa, S. Ogden,
D. R. Hersey, S. Mascia, J. M. B. Evans, R. D. Braatz
and P. I. Barton, Org. Process Res. Dev., DOI: 10.1021/
op500104d; (b) P. L. Heider, S. C. Born, S. Basak,
B. Benyahia, R. Lakerveld, H. Zhang, R. Hogan, L. Buchbinder,
A. Wolfe, S. Mascia, J. M. B. Evans, T. F. Jamison and
K. F. Jensen, Org. Process Res. Dev., 2014, 18, 402–409;
(c) S. Mascia, P. L. Heider, H. Zhang, R. Lakerveld,
B. Benyahia, P. I. Barton, R. D. Braatz, C. L. Cooney,
J. M. B. Evans, T. F. Jamison, K. F. Jensen, A. S. Myerson
and B. L. Trout, Angew. Chem., Int. Ed., 2013, 52, 12359–
12363; (d) S. Hanessian and E. Chénard, Org. Lett., 2012,
14, 3222–3225; (e) Y. Nakamura, Y. Ogawa, C. Suzuki,
T. Fujimoto, S. Miyazaki, K. Tamaki, T. Nishi and
H. Suemune, Heterocycles, 2011, 83, 1587–1602; (f ) J. Slade,
H. Liu, M. Prashad and K. Prasad, Tetrahedron Lett., 2011,
52, 4349–4352; (g) S. Hanessian, S. Guesné and E. Chénard,
Org. Lett., 2010, 12, 1816–1819; (h) J. M. Wood and
J. Maibaum, in Aspartic Acid Proteases as Therapeutic
Targets, , ed. A. K. Gosh, Wiley-VCH, 2010, ch. 10, vol. 45,
pp. 265–295; (i) R. Göschke, S. Stutz, V. Rasetti, N.-C. Cohen,
J. Rahuel, P. Rigollier, H.-P. Baum, P. Forgiarini,
C. R. Schnell, T. Wagner, M. G. Gruetter, W. Fuhrer,
W. Schilling, F. Cumin, J. M. Wood and J. Maibaum,
J. Med. Chem., 2007, 50, 4818–4831; ( j) J. Maibaum,
S. Stutz, R. Göschke, P. Rigollier, Y. Yamaguchi, F. Cumin,
J. Rahuel, H.-P. Baum, N.-C. Cohen, C. R. Schnell,
W. Fuhrer, M. G. Gruetter, W. Schilling and J. M. Wood,
J. Med. Chem., 2007, 50, 4832–4844; (k) K. B. Lindsay and
T. Skrydstrup, J. Org. Chem., 2006, 71, 4766–4777;
(l) H. Dong, Z.-L. Zhang, J.-H. Huang, R. Ma, S.-H. Chen
and G. Li, Tetrahedron Lett., 2005, 46, 6337–6340;
(m) D. A. Sandham, R. J. Taylor, J. S. Carey and A. Fässler,
Tetrahedron Lett., 2000, 41, 10091–10094; (n) H. Rüeger,
S. Stutz, R. Göschke, F. Spindler and J. Maibaum, Tetrahe-
dron Lett., 2000, 41, 10085–10089; (o) M. S. Reddy,
S. T. Rajan, S. Eswaraiah, G. V. Reddy, K. R. S. Reddy and
M. S. Reddy, WO Pat, WO148392A1, 2011; (p) T. G. Gant and
M. Shahbaz, WO Pat, WO059967A2, 2010; (q) T. G. Gant and
M. Shahbaz, US Pat, US0124550A1, 2010; (r) P. Herold,
S. Stutz and F. Spindler, WO Pat, WO0202508A1, 2002;
(s) S. Stutz and P. Herold, US Pat, US0181765A1, 2003;
(t) P. Herold and S. Stutz, WO Pat, WO0202487A1, 2002;
(u) K. Davor and Z. Pok, EP Pat, EP2062874A1, 2009.
4 For selected reviews, see: (a) M. Schuster and S. Blechert,
Angew. Chem., Int. Ed. Engl., 1997, 36, 2036–2056;
(b) S. J. Connon and S. Blechert, Angew. Chem., Int. Ed.,
2003, 42, 1900–1923.
5 For selected examples, see: (a) A. K. Chatterjee,
J. P. Morgan, M. Scholl and R. H. Grubbs, J. Am. Chem.
Soc., 2000, 122, 3783–3784; (b) S. D. Goldberg and
R. H. Grubbs, Angew. Chem., Int. Ed., 2002, 41, 807–810;
(c) A. K. Chatterjee and R. H. Grubbs, Angew. Chem., Int.
Ed., 2002, 41, 3171–3174; (d) A. K. Chatterjee, T.-L. Choi,
D. P. Sanders and R. H. Grubbs, J. Am. Chem. Soc., 2003,
125, 11360–11370; (e) K. Endo and R. H. Grubbs, J. Am.
Chem. Soc., 2011, 133, 8525–8527; (f ) B. K. Keitz, K. Endo,
M. B. Herbert and R. H. Grubbs, J. Am. Chem. Soc., 2011,
133, 9686–9688; (g) B. K. Keitz, A. Fedorov and
R. H. Grubbs, J. Am. Chem. Soc., 2012, 134, 2040–2043;
(h) M. B. Herbert, V. M. Marx, R. L. Pederson and
R. H. Grubbs, Angew. Chem., Int. Ed., 2013, 52, 310–314.
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2015 Org. Biomol. Chem., 2015, 13, 1133–1140 | 1139
Pu
bl
is
he
d 
on
 1
3 
N
ov
em
be
r 2
01
4.
 D
ow
nl
oa
de
d 
by
 C
ha
ng
ch
un
 In
st
itu
te
 o
f A
pp
lie
d 
C
he
m
is
try
, C
A
S 
on
 0
4/
02
/2
01
5 
02
:1
0:
28
. 
View Article Online
6 (a) D. A. Evans and J. M. Takacs, Tetrahedron Lett., 1980, 21,
4233–4236; (b) D. A. Evans, J. Bartroli and T. L. Shih, J. Am.
Chem. Soc., 1981, 103, 2127–2129.
7 (a) F. Rolla, J. Org. Chem., 1981, 46, 3909–3911;
(b) M. Sawamura, Y. Kawaguchi, K. Sato and E. Nakamura,
Chem. Lett., 1997, 26, 705–706.
8 N. Satyamurthi, J. Singh and I. S. Aidhen, Synthesis, 2000,
375–382.
9 R. F. Nystrom and C. R. A. Berger, J. Am. Chem. Soc., 1958,
80, 2896–2898.
10 S. H. Hong, D. P. Sanders, C. W. Lee and R. H. Grubbs,
J. Am. Chem. Soc., 2005, 127, 17160–17161.
11 For an early review, see: J. Boutagy and R. Thomas, Chem.
Rev., 1974, 74, 87–99.
12 (a) T. E. Nielsen and M. Meldal, Org. Lett., 2005, 7, 2695–
2698; (b) W. Yu, Y. Mei, Y. Kang, Z. Hua and Z. Jin, Org.
Lett., 2004, 6, 3217–3219.
13 (a) W. J. Miao, Y. Z. Gao, X. Q. Li, Y. X. Gao, G. Tang and
Y. F. Zhao, Adv. Synth. Catal., 2012, 354, 2659–2664;
(b) Z.-S. Chen, Z.-Z. Zhou, H.-L. Hua, X.-H. Duan, J.-Y. Luo,
J. Wang, P.-X. Zhou and Y.-M. Liang, Tetrahedron, 2013, 69,
1065–1068.
14 A. K. Bhattacharya and G. Thyagarajan, Chem. Rev., 1981,
81, 415–430.
15 For selected examples, see: (a) S. V. Jeught and
C. V. Stevens, Chem. Rev., 2009, 109, 2672–2702;
(b) A. Kermagoret and P. Braunstein, Dalton Trans., 2008,
822–831; (c) J. M. Tukacs, D. Kiraly, A. Stradi, G. Novodarszki,
Z. Eke, G. Dibo, T. Kegl and L. T. Mika, Green Chem., 2012,
14, 2057–2065.
16 R. Dumeunier and I. E. Markó, in Modern Carbonyl Olefina-
tion, ed. T. Takeda, Wiley-VCH, Weinheim, 2004, ch. 3,
pp. 104–150.
17 (a) P. R. Blakemore, W. J. Cole, P. J. Kocienski and
A. Morley, Synlett, 1998, 26–28; (b) T. Satoh, N. Yamada and
T. Asano, Tetrahedron Lett., 1998, 39, 6935–6938.
18 J. A. May and B. M. Stoltz, J. Am. Chem. Soc., 2002, 124,
12426–12427.
19 P. R. Blakemore, J. Chem. Soc., Perkin Trans. 1, 2002, 2563–2585.
20 J. Pospíšil, Tetrahedron Lett., 2011, 52, 2348–2352.
21 For original publications, see: (a) D. C. Behenna and
B. M. Stoltz, J. Am. Chem. Soc., 2004, 126, 15044–15045;
(b) B. M. Trost and J. Xu, J. Am. Chem. Soc., 2005, 127,
2846–2847. For review articles, see: (c) J. T. Mohr,
M. R. Krout and B. M. Stoltz, Nature, 2008, 455, 323–332;
(d) J. T. Mohr and B. M. Stoltz, Chem. – Asian J., 2007, 2,
1476–1491; (e) S.-L. You and L.-X. Dai, Angew. Chem., Int.
Ed., 2006, 45, 5246–5248.
Paper Organic & Biomolecular Chemistry
1140 | Org. Biomol. Chem., 2015, 13, 1133–1140 This journal is © The Royal Society of Chemistry 2015
Pu
bl
is
he
d 
on
 1
3 
N
ov
em
be
r 2
01
4.
 D
ow
nl
oa
de
d 
by
 C
ha
ng
ch
un
 In
st
itu
te
 o
f A
pp
lie
d 
C
he
m
is
try
, C
A
S 
on
 0
4/
02
/2
01
5 
02
:1
0:
28
. 
View Article Online
